Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen were at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Advancing Precision Medicine

In addition to showcasing the new ultra-sensitive mutation detection technology superRCA, our participation in CYTO 2024 underscores Rarity Bioscience’s dedication to advancing precision medicine. The superRCA technology enables identification of rare tumor-specific mutations, even at low frequencies, with high specificity and ultra-high sensitivity. We believe this has the potential to revolutionize the monitoring and treatment landscape for diseases like acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) and solid tumours. 

Presentation at CYTO 2024

While there was a lot of focus on the new nano flow instruments for analysis of extracellular vesicles, as well as updates on the menus of spectral flow, the most novel application came from Rarity Bioscience’s Lei Chen in the presentation on detection of nucleic acid using regular flow cytometry. Attendees were enlightened about the revolutionary superRCA technology, marveling at its precision in detecting genetic mutations at ultra-low levels. 

A strand of DNA is only 2,5nm in size, and practically undetectable, but the superRCA assays convert tiny DNA fragments into flow detectable particles. While still almost invisible on regular scatter parameters, the superRCA particles are extremely fluorescent and easy to gate and enumerate with extreme accuracy. 

It was undeniably a presentation that left a lasting impact, one not to be missed! 

Lei Chen at CYTO 2024
Lei Chen at CYTO 2024

If you want to learn more about the superRCA technology, go to our technology page:

Thanks CYTO 2024 for a fantastic conference! 

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »